Qiagen liquid biopsy to guide Inovio immunotherapy

By LabPulse.com staff writers

May 17, 2019 -- Qiagen is developing a liquid biopsy companion diagnostic for Inovio's investigational VGX-3100 immunotherapy for the nonsurgical treatment of advanced cervical dysplasia associated with the cancer-causing human papillomavirus (HPV).

The test will be used to help predict which patients will benefit from receiving VGX-3100, a DNA-based immunotherapy in phase III development for the treatment of women positive for HPV types 16 and 18, which cause most cervical cancers and high-grade squamous intraepithelial lesions, the two companies said in a joint statement on May 16. Inovio plans to file a biologics license application (BLA) for the drug in the U.S. in 2021.

The agreement on a liquid biopsy companion diagnostic grew out of a partnership to develop novel microRNA biomarkers. Qiagen's digene HC2 high-risk HPV DNA test is approved for use in the U.S. and Canada. Financial terms of the deal were not disclosed.

LabCorp launches Qiagen's FGFR test for bladder cancer
LabCorp announced on May 10 that it has begun offering Qiagen's therascreen companion diagnostic for detecting FGFR mutations in bladder cancer.
Kalorama's notable product launches for clinical labs in Q1 2019
What were some of the most notable new product launches for clinical laboratories in the first quarter of 2019? Bruce Carlson of market research firm...

Copyright © 2019 LabPulse.com

Last Updated np 5/17/2019 1:44:38 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current